Abstract:Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease with obscure pathogenesis. Increasing evidence suggests that cellular senescence is an important mechanism underlying in IPF. Clinical treatment with drugs, such as pirfenidone and nintedanib, reduces the risk of acute exacerbation and delays the decline of pulmonary function in patients with mild to moderate pulmonary fibrosis, and with adverse reactions. Hesperidin was previously shown to alleviate pulmonary fibrosis in rats by attenuating the inflammation response. Our previous research indicated that the Citrus alkaline extracts, hesperidin as the main active ingredient, could exert anti-pulmonary fibrosis effects by inhibiting the senescence of lung fibroblasts. However, whether hesperidin could ameliorate pulmonary fibrosis by inhibiting fibroblast senescence needed further study. Purpose: This work aimed to investigate whether and how hesperidin can inhibit lung fibroblast senescence and thereby alleviate pulmonary fibrosis METHODS: Bleomycin was used to establish a mouse model of pulmonary fibrosis and doxorubicin was used to establish a model of cellular senescence in MRC-5 cells in vitro. The therapeutic effects of hesperidin on pulmonary fibrosis using haematoxylin-eosin staining, Masson staining, enzyme-linked immunosorbent assay, immunohistochemistry, western blotting and quantitative Real-Time PCR. The anti-senescent effect of hesperidin in vivo and in vitro was assessed by western blotting, quantitative Real-Time PCR and senescence-associated β-galactosidase RESULTS: We demonstrated that hesperidin could alleviate bleomycin-induced pulmonary fibrosis in mice. The expression level of senescence marker proteins p53, p21, and p16 was were downregulated, along with the myofibroblast marker α-SMA. The number of senescence-associated β-galactosidase-positive cells was significantly reduced by hesperidin intervention in vivo and in vitro. In addition, hesperidin could inhibit the IL6/STAT3 signaling pathway. Furthermore, suppression of the IL-6/STAT3 signaling pathway by pretreatment with the IL-6 inhibitor LMT-28 attenuating effect of hesperidin on fibroblast senescence in vitro. Conclusions: These data illustrated that hesperidin may be potentially used in the treatment of IPF based on its ability to inhibit lung fibroblast senescence.

Human Epididymis Protein 4 (HE4): more than a marker for lung injury?

Elevated Serum Human Epididymis Protein 4 is Associated with Disease Severity and Worse Survival in Idiopathic Pulmonary Fibrosis: a Cohort Study

Prognostic Value of Human Epididymis Protein 4 in Connective Tissue Disease-Associated Interstitial Lung Disease with a Usual Interstitial Pneumonia Phenotype

Human Epididymis Protein 4 is Associated with Severity and Poor Prognosis of Connective Tissue Disease-Associated Interstitial Lung Disease with Usual Interstitial Pneumonia Pattern

Serum Human Epididymis Protein 4 as a Novel Biomarker in Identifying Patients With Interstitial Lung Disease in Rheumatoid Arthritis

SERUM HUMAN EPIDIDYMIS PROTEIN 4 LEVELS PREDICT CLINICAL WORSENING IN PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION

Effect of human epididymis protein 4 on hyperoxia-induced bronchial dysplasia in newborn rats

HE4 Predicts Progressive Fibrosis and Cardiovascular Events in Patients With Dilated Cardiomyopathy

Human Epididymis Protein 4 As a Clinical Biomarker in Identifying Interstitial Lung Disease in Patients with Idiopathic Inflammatory Myopathies

Identification of Ephrin type-B receptor 4 as a critical mediator of tissue fibrosis

Overexpression of KLF4 Suppresses Pulmonary Fibrosis Through the HIF-1α/Endoplasmic Reticulum Stress Signaling Pathway.

Regulation of extracellular matrix gene expression and biosynthetic pathways in pulmonary fibroblasts by HSF1

Hesperidin inhibits lung fibroblast senescence via IL-6/STAT3 signaling pathway to suppress pulmonary fibrosis

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) activates p38 to affect pulmonary fibrosis

Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases

Silencing HE4 alleviates the renal fibrosis in lupus nephritis mice by regulating the C3/MMPs/prss axis

Evogliptin Attenuates Bleomycin-Induced Lung Fibrosis Via Inhibiting TGF-β/Smad Signaling in Fibroblast

Exploring the Antifibrotic Potential of the heparan sulfate mimetic OTR4120: Insights from Preclinical Models

Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2

HE4 Promotes Events Associated with Metastatic Ovarian Cancer Via Regulation of the Extracellular Matrix

Dihydromyricetin Alleviates Pulmonary Fibrosis by Regulating Abnormal Fibroblasts Through the STAT3/p-STAT3/GLUT1 Signaling Pathway